| Product Name |
NLRP1/NALP1 Antibody |
| Antibody Type |
Primary Antibodies |
| Antigen Alias |
NACHT-, LRR- and PYD-containing Protein 1; NLRP1; Caspase Recruitment Domain-containing Protein 7; Death Effector Filament-forming Ced-4-like Apoptosis Protein; Nucleotide-binding Domain and Caspase Recruitment Domain |
| Product description |
NALP1/NLRP1 is able to form cytoplasmic structures termed death effector filaments. It enhances and stimulates apoptosis through activation of different caspase cascades. It is involved in the activation of caspase-1 and caspase-5 as part of the NALP1 inflammasome complex which leads to processing and release of IL1B and IL18. Genetic variations in the NLRP1/NALP1 gene are associated with susceptibility to vitiligo-associated multiple autoimmune disease type 1, an autoimmune disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus. |
| Immunogen |
Synthetic peptide corresponding to aa 2-25 (A2GGAWGRLACYLEFLKKEELKEFQ25) at the N-terminus of human NLRP1/NALP1. |